PURPOSE: To provide an overview on smoldering (asymptomatic) multiple myeloma (SMM) including current diagnostic criteria, predictors of progression, pattern of progression, and outcome. DESIGN: A comprehensive review of the literature on risk factors for progression, treatment attempts to delay progression and outcome in patients with SMM. RESULTS: The risk factors for progression of SMM include: plasma cell mass including M-protein size and percentage of bone marrow clonal plasma cells (BMPC), abnormal free light chain ratio, proportion of phenotypically abnormal BMPC, immunoparesis, evolution pattern (evolving v nonevolving), and pattern of magnetic resonance imaging abnormalities. Most patients with SMM progress with anemia and/or skeletal involvement. Immediate therapy with cytotoxic agents, such as melphalan/prednisone has not resulted in improved outcome. Patients should not be treated until progressive disease with end-organ damage occurs. Increasing anemia is the most reliable indicator of progression. CONCLUSION: These recently recognized predictors of outcome may be helpful for better disease monitoring and for investigation of new treatment approaches. Thus, recommendations for follow-up every to 3 to 6 months depending on the risk of progression are suggested, and clinical trials with new noncytotoxic biologically derived agents to delay progression, particularly in high-risk patients, are ongoing.
PURPOSE: To provide an overview on smoldering (asymptomatic) multiple myeloma (SMM) including current diagnostic criteria, predictors of progression, pattern of progression, and outcome. DESIGN: A comprehensive review of the literature on risk factors for progression, treatment attempts to delay progression and outcome in patients with SMM. RESULTS: The risk factors for progression of SMM include: plasma cell mass including M-protein size and percentage of bone marrow clonal plasma cells (BMPC), abnormal free light chain ratio, proportion of phenotypically abnormal BMPC, immunoparesis, evolution pattern (evolving v nonevolving), and pattern of magnetic resonance imaging abnormalities. Most patients with SMM progress with anemia and/or skeletal involvement. Immediate therapy with cytotoxic agents, such as melphalan/prednisone has not resulted in improved outcome. Patients should not be treated until progressive disease with end-organ damage occurs. Increasing anemia is the most reliable indicator of progression. CONCLUSION: These recently recognized predictors of outcome may be helpful for better disease monitoring and for investigation of new treatment approaches. Thus, recommendations for follow-up every to 3 to 6 months depending on the risk of progression are suggested, and clinical trials with new noncytotoxic biologically derived agents to delay progression, particularly in high-risk patients, are ongoing.
Authors: S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie Journal: N Engl J Med Date: 1999-11-18 Impact factor: 91.245
Authors: Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton Journal: N Engl J Med Date: 2002-02-21 Impact factor: 91.245
Authors: John A Lust; Martha Q Lacy; Steven R Zeldenrust; Angela Dispenzieri; Morie A Gertz; Thomas E Witzig; Shaji Kumar; Suzanne R Hayman; Stephen J Russell; Francis K Buadi; Susan M Geyer; Megan E Campbell; Robert A Kyle; S Vincent Rajkumar; Philip R Greipp; Michael P Kline; Yuning Xiong; Laurie L Moon-Tasson; Kathleen A Donovan Journal: Mayo Clin Proc Date: 2009-02 Impact factor: 7.616
Authors: Alejandro Martín; Ramón García-Sanz; José Hernández; Joan Bladé; Begoña Suquía; Javier Fernández-Calvo; Marcos González; Gema Mateo; Alberto Orfao; Jesus F San Miguel Journal: Br J Haematol Date: 2002-07 Impact factor: 6.998
Authors: M Dimopoulos; E Terpos; R L Comenzo; P Tosi; M Beksac; O Sezer; D Siegel; H Lokhorst; S Kumar; S V Rajkumar; R Niesvizky; L A Moulopoulos; B G M Durie Journal: Leukemia Date: 2009-05-07 Impact factor: 11.528
Authors: A Riccardi; O Mora; C Tinelli; D Valentini; S Brugnatelli; R Spanedda; A De Paoli; L Barbarano; M Di Stasi; M Giordano; C Delfini; G Nicoletti; C Bergonzi; E Rinaldi; L Piccinini; E Ascari Journal: Br J Cancer Date: 2000-04 Impact factor: 7.640
Authors: E Kastritis; F Zagouri; A Symeonidis; M Roussou; A Sioni; A Pouli; S Delimpasi; E Katodritou; E Michalis; M Michael; E Hatzimichael; A Vassou; P Repousis; A Christophoridou; Z Kartasis; E Stefanoudaki; C Megalakaki; S Giannouli; M-C Kyrtsonis; K Konstantopoulos; M Spyroupoulou-Vlachou; E Terpos; M A Dimopoulos Journal: Leukemia Date: 2014-03-18 Impact factor: 11.528
Authors: Kristen Detweiler-Short; Suzanne Hayman; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Shaji Kumar; Steven R Zeldenrust; Stephen J Russell; John A Lust; Robert A Kyle; Philip R Greipp; Thomas E Witzig; S Vincent Rajkumar Journal: Am J Hematol Date: 2010-10 Impact factor: 10.047
Authors: T E Witzig; K M Laumann; M Q Lacy; S R Hayman; A Dispenzieri; S Kumar; C B Reeder; V Roy; J A Lust; M A Gertz; P R Greipp; H Hassoun; S J Mandrekar; S V Rajkumar Journal: Leukemia Date: 2012-08-20 Impact factor: 11.528